FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/01/2023
Back to search
Official data from USPTO
MEDIGENE IMMUNOTHERAPIES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
MEDIGENE IMMUNOTHERAPIES
ST13
US500000079309216Class
5, 42, 44
Filing
79309216
Registration
6932587
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
05/01/2023
Classification
Registered
Trademark type
Word
Nice classes
5, 42, 44
Filing date
02/23/2021
Registration date
12/27/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/27/2022
Last transaction
12/27/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
DE
Examiner
CIANCI, RYAN
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Medigene Immunotherapies GmbH
Representatives
Lisa C. Pavento Meunier Carlin & Curfman LLC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for humans and animalsvaccinesserums for medical purposesdiagnostic preparations for medical purposes for treating cancerin particular manufactured using molecular biologicalgenetic engineering and biotechnological methods; test kits for principally comprised of diagnostic preparations for medical purposes that contains at least one of soluble t-cell receptorsgenetically modified cells for determining the type and existence of a tumour in a patientin particular manufactured using molecular biologicalgenetic engineering and biotechnological methods; proteins and cellsimmune cells carrying a target specific effector proteinprotein conjugatespeptidesenzymes and enzyme preparationsin particular antibodies and t-cell proteinsall for medical purposes; t-cellsdendritic cells other immune system cellsvirusesall for medical purposes;plant extracts for medical purposes; medicinesvaccinesadjuvantsserums all for immunotherapy and the treatment of benign and malignant tumourshaematological tumoursinflammatory disordersneurodegenerative disordersautoimmune conditions in particular manufactured using molecular biologicalgenetic engineering and biotechnological methods; test kits and diagnostic agents comprised of medical diagnostic preparations that contain at least one of soluble t-cell receptors and genetically modified cells for the diagnosis of benign and malignant tumourshaematological tumoursinflammatory disordersneurodegenerative disordersautoimmune conditions in particular manufactured using molecular biologicalgenetic engineering and biotechnological methods
Class 42
Custom molecular biology and biotechnology laboratory servicesin particular custom research and development in the field of medical and veterinary diagnosis and treatment using molecular biologicalgenetic engineering and biotechnological methods to the specifications of othersin the field of screening for pharmaceutically active components; development of custom test procedures and custom test kits in the field of biotechnology and medicine to the specification of others
Class 44
Medical analysis and medical consulting in connection with the treatment of individualsin particular in the field of precancerous cellsbenign and malignant tumoursautoimmune diseases and immunotherapy
Publications
History of USPTO decisions and trademark events.
35 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/06/2023
FIMP
FINAL DISPOSITION PROCESSED
04/06/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/27/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
12/27/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/17/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/11/2022
PUBO
PUBLISHED FOR OPPOSITION
10/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
10/10/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/28/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/28/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/21/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/21/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/21/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/07/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
09/07/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/07/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
09/07/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/07/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/14/2022
GNFR
FINAL REFUSAL E-MAILED
04/14/2022
CNFR
FINAL REFUSAL WRITTEN
04/14/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/30/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/30/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/30/2022
RFNT
REFUSAL PROCESSED BY IB
10/30/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/01/2021
RFRR
REFUSAL PROCESSED BY MPU
10/01/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/27/2021
CNRT
NON-FINAL ACTION WRITTEN
09/26/2021
DOCK
ASSIGNED TO EXAMINER
09/17/2021
MAFR
APPLICATION FILING RECEIPT MAILED
04/27/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/23/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/22/2021
Continuous trademark protection
Get notified about every new filing that threatens MEDIGENE IMMUNOTHERAPIES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.